Petitioners in Seattle are asking a federal court for a rehearing on a decision stemming from an action filed in December 2022, seeking review of a DEA final decision denying their original petition to initiate rulemaking proceedings to transfer psilocybin from schedule I to schedule II. The Seattle physician seeking to loosen restrictions on psilocybin wants the Drug Enforcement Administration to refer his rescheduling petition to federal health authorities. This rehearing petition comes nearly two months after a circuit panel remanded the doctor’s request to change psilocybin’s status back to the DEA and ordered the agency to clarify why it believes the drug should remain a Schedule I substance.
